Effect of CEAG on Inflammation and Endothelial Function

Completed · Not applicable · Has a placebo group

Conditions studied: Inflammation, Endothelial Dysfunction

In brief

The purpose of the study is to look at the effect a dietary supplement called CEAG \[Curcuminoids, EPA (Omega-3), Astaxanthin and Gamma Linolenic Acid (GLA)\] has on inflammation and endothelial (inner layer of the blood vessels) function and whether it causes a lowering of blood pressure.The endothelium plays in an important role in blood pressure.

Key facts

Study ID

NCT03906825

Run by

Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center

People needed

80

Starts

2018-05-17

Expected to finish

2018-08-13

Last updated by the study team

2020-04-09

Who can join

Age: 18 and older, up to 75. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• age 18-75 years
• BP 121-140/81-90 mm Hg on average
• Body Mass Index (BMI) 18-40.

You may not qualify if…

• free of chronic diseases including cancer or rheumatologic disorders
• weight in excess of 350 pounds
• bleeding disorder
• history of myocardial infarction or all types of revascularization procedures, second or third degree heart block with or without a pacemaker
• angina pectoris of any type
• concurrent potentially life-threatening arrhythmia or symptomatic arrhythmia clinically significant valvular heart disease
• history of malignancy of any organ system, treated or untreated, within the past 5 years whether or not there is evidence of local recurrence or metastases, (with the exception of localized basal cell carcinoma of the skin)
• serum creatinine > 2.0 mg/dl
• concurrent enrollment in another placebo-controlled trial.

Where it is running

• Lundquist Institute for Biomedical Innovation at Harbor UCLA Medical Center — Torrance, California, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.